Nakashima N, Umeda F, Yamauchi T, Ishii H, Hisatomi A, Nawata H, Masuko H, Nakayama K, Tatematsu A
Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
J Lab Clin Med. 1992 Jul;120(1):78-85.
Although platelet-derived growth factor (PDGF) is thought to be a major mediator of atherosclerotic disease, the pathophysiology of diabetic vasculopathy, including atherosclerosis, is unclear. By means of an enzyme immunoassay that used a monoclonal antibody against human PDGF-B chain, PDGF-like immunoreactivity was determined in serum, platelet-poor plasma, and platelet lysate of 28 patients with non-insulin-dependent diabetes mellitus and 11 control subjects. Growth-promoting activity was also measured by tritiated thymidine incorporation into DNA of cultured human fibroblasts. The PDGF-like immunoreactivity in serum was correlated (r = 0.42; p less than 0.01) with that in platelet lysate prepared from a fixed volume of blood. Furthermore, a correlation (r = 0.70; p less than 0.001) was found between the PDGF-like immunoreactivity and the growth-promoting activity in platelet lysate but not in serum. There was no significant difference between patients with diabetes and control subjects with respect to the PDGF-like immunoreactivity in serum or in platelet lysate (38.2 +/- 2.2 vs 42.8 +/- 3.1 ng/ml or 49.1 +/- 2.4 vs 56.2 +/- 3.4 ng/mg protein; mean +/- SEM). In contrast, the serum growth-promoting activity was lower (p less than 0.05) in patients with diabetes than in control subjects (88.1% +/- 7.1% vs 117.4% +/- 6.9%) and there was a negative correlation (r = -0.39; p less than 0.05) between the serum growth-promoting activity and the fasting plasma glucose level. The growth-promoting activity in platelet lysate of patients with diabetes did not differ from that of the control subjects (59.9% +/- 11.6% vs 65.9% +/- 11.2%).(ABSTRACT TRUNCATED AT 250 WORDS)
尽管血小板衍生生长因子（PDGF）被认为是动脉粥样硬化疾病的主要介质，但包括动脉粥样硬化在内的糖尿病血管病变的病理生理学尚不清楚。通过使用抗人PDGF - B链单克隆抗体的酶免疫测定法，测定了28例非胰岛素依赖型糖尿病患者和11例对照者血清、少血小板血浆及血小板裂解物中的PDGF样免疫反应性。还通过将氚标记的胸腺嘧啶核苷掺入培养的人成纤维细胞DNA中来测量生长促进活性。血清中的PDGF样免疫反应性与从固定体积血液制备的血小板裂解物中的免疫反应性相关（r = 0.42；p < 0.01）。此外，在血小板裂解物中发现PDGF样免疫反应性与生长促进活性之间存在相关性（r = 0.70；p < 0.001），但在血清中未发现这种相关性。糖尿病患者与对照者在血清或血小板裂解物中的PDGF样免疫反应性方面无显著差异（38.2±2.2对42.8±3.1 ng/ml或49.1±2.4对56.2±3.4 ng/mg蛋白质；平均值±标准误）。相比之下，糖尿病患者的血清生长促进活性低于对照者（p < 0.05）（88.1%±7.1%对117.4%±6.9%），并且血清生长促进活性与空腹血糖水平之间存在负相关（r = -0.39；p < 0.05）。糖尿病患者血小板裂解物中的生长促进活性与对照者无差异（59.9%±11.6%对65.9%±11.2%）。（摘要截于250字）
